Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

I-Mab and MorphoSys to Test C5aR1 Antibody in the US

publication date: Sep 18, 2020

Shanghai's I-Mab and MorphoSys AG of Munich announced they have permission to start US trials of an anti-C5aR1 antibody in patients with advanced solid tumors. The candidate is designed to be used together with checkpoint inhibitors. Two years ago, I-Mab in-licensed greater China rights to the novel antibody in a $105 million agreement. As part of the deal, I-Mab agreed to conduct ex-China trials of the candidate in return for a single-digit royalty on sales outside of China. More details....

Stock Symbols: (NSDQ: IMAB) (FSE: MOR)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.